Drug intelligence / Profile preview

SN-07

Development stage: Unknown

Overview

SN-07 is a novel macromolecular antitumor antibiotic. Studies on mouse lymphoid leukemia L1210 cells have shown that SN-07 exhibits cytotoxicity by inhibiting both RNA and DNA syntheses. It also induces DNA interstrand cross-links and DNA breaks. The drug causes inhibition of cell cycle progression, with cells progressing to the G2 phase at cytostatic concentrations and showing typical inhibition at cytocidal concentrations.

Targets

DNA

Beyond the preview

Go deeper on SN-07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SN-07.

Explore the full profile